Legato Capital Management LLC Buys Shares of 24,704 Vera Therapeutics, Inc. $VERA

Legato Capital Management LLC bought a new stake in shares of Vera Therapeutics, Inc. (NASDAQ:VERA) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 24,704 shares of the company’s stock, valued at approximately $1,251,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. GAMMA Investing LLC raised its position in Vera Therapeutics by 50.5% during the 4th quarter. GAMMA Investing LLC now owns 703 shares of the company’s stock valued at $36,000 after purchasing an additional 236 shares in the last quarter. Quantbot Technologies LP bought a new stake in Vera Therapeutics during the 2nd quarter valued at $51,000. Tower Research Capital LLC TRC raised its position in Vera Therapeutics by 192.9% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,186 shares of the company’s stock valued at $99,000 after purchasing an additional 2,757 shares in the last quarter. AlphaQuest LLC raised its position in Vera Therapeutics by 414.2% during the 3rd quarter. AlphaQuest LLC now owns 5,214 shares of the company’s stock valued at $152,000 after purchasing an additional 4,200 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Vera Therapeutics by 25.9% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,106 shares of the company’s stock valued at $157,000 after acquiring an additional 639 shares during the period. 99.21% of the stock is owned by institutional investors.

Insiders Place Their Bets

In related news, CEO Marshall Fordyce sold 22,951 shares of the business’s stock in a transaction on Tuesday, April 14th. The stock was sold at an average price of $44.05, for a total transaction of $1,010,991.55. Following the transaction, the chief executive officer directly owned 235,244 shares in the company, valued at $10,362,498.20. The trade was a 8.89% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 15.90% of the stock is currently owned by company insiders.

Vera Therapeutics Stock Performance

Shares of NASDAQ:VERA opened at $34.04 on Monday. Vera Therapeutics, Inc. has a 12-month low of $18.76 and a 12-month high of $56.05. The business’s fifty day simple moving average is $39.02 and its 200-day simple moving average is $40.88. The company has a market capitalization of $2.44 billion, a PE ratio of -6.14 and a beta of 0.96. The company has a current ratio of 13.64, a quick ratio of 13.64 and a debt-to-equity ratio of 0.15.

Vera Therapeutics (NASDAQ:VERA) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($1.69) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.33) by ($0.36). During the same quarter last year, the firm posted ($0.81) earnings per share. As a group, equities research analysts predict that Vera Therapeutics, Inc. will post -6.14 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

VERA has been the topic of a number of analyst reports. Evercore set a $91.00 price target on Vera Therapeutics in a report on Friday, May 15th. HC Wainwright lifted their price target on Vera Therapeutics from $90.00 to $110.00 and gave the company a “buy” rating in a report on Monday, March 2nd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Vera Therapeutics in a report on Monday, April 20th. Finally, Wolfe Research upgraded Vera Therapeutics from a “peer perform” rating to an “outperform” rating and set a $88.00 price target on the stock in a report on Wednesday, March 11th. Ten research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $79.00.

Vera Therapeutics Company Profile

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.